AstraZeneca Results Presentation Deck
2
Forward-looking statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the
Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations,
performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or
other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements,
by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially
different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document
and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the
words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ
materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other thingsthe risk of
failure or delay in delivery of pipeline or launch of new medicines: the risk of failure to meet regulatory or ethical requirements for medicine
development or approval, the risk of failures or delays in the quality or execution of the Group's commercial strategies, the risk of pricing, affordability,
access and competitive pressures, the risk of failure to maintain supply of compliant, quality medicines, the risk of illegal trade in the Group's medicines,
the impact of reliance on third-party goods and services, the risk of failure in information technology or cybersecurity, the risk of failure of critical
processes, the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives, the risk of failure to
attract, develop, engage and retain a diverse, talented and capable workforce, the risk of failure to meet regulatory or ethical expectations on
environmental impact, including climate change, the risk of the safety and efficacy of marketed medicines being questioned, the risk of adverse outcome
of litigation and/or governmental investigations, intellectual property-related risks to our products, the risk of failure to achieve strategic plans or meet
targets or expectations, the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue
to mitigate these risks, and on the Group's operations, financial results or financial condition, the risk of failure in financial control or the occurrence of
fraud, the risk of unexpected deterioration in the Group's financial position. Nothing in this document, or any related presentation/webcast, should be
construed as a profit forecast.View entire presentation